Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New clinic aims to ease the journey for women cancer survivors

NCT ID NCT05035173

Knowledge-focused Sponsor: University College Cork Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special survivorship clinic, combined with an app for reporting symptoms, is practical for women who have finished curative treatment for early-stage breast, cervical, or endometrial cancer. Two hundred women visited the clinic at the start and end of the 12-month study, and used electronic surveys to track their symptoms. The goal was to see if women would use the service and if it could help catch problems early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Survivorship clinic with electronic patient-reported outcome (ePRO) symptom monitoring
What this could lead to
If successful, this could show that a dedicated survivorship clinic with digital symptom tracking is feasible and helpful for women after cancer treatment.
What could go wrong
This is a small feasibility study (200 participants) with no control group, so it cannot prove whether the clinic improves health outcomes. Results may not apply to other cancers or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Mar 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged \> or = 18 years. 2. Ability to read and understand English. 3. Access to internet. 4. Early-stage breast/gynaecologic cancer within 12 months of completion of primary curative therapy: * Breast cancer: Stage I-III hormone receptor-positive (defined as estrogen receptor and/or progesterone receptor ≥ 1%) and HER2-negative per ASCO-CAP guidelines on or recommended to commence adjuvant endocrine therapy during the study period. * Cervical cancer: Stage I to III treated with curative intent. * Endometrial cancer: treated with curative intent adjuvant radiotherapy +/- chemotherapy Exclusion Criteria: 1. Patients who are not treated with curative intent as above. 2. Patients with premalignant disease. 3. Persons who, in the opinion of the researcher or supervising clinician, are unable to cooperate adequately with the study protocol. 4. Recent (within 12 months) participation in a study/programme involving a lifestyle intervention (e.g diet, exercise, survivorship). Note: Per discretion of PI as to whether may impact the outcome of this study intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer endometrial cancer endometrium neoplasm hormone receptor-positive breast cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Cervical cancer Endometrial cancer Survivorship

Contacts and locations

Locations

  • Cork University Hospital

    Cork, Cork, T12 DFK4, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.